Efficacy and Safety of Apremilast in Psoriasis

Sponsor
Ghurki Trust and Teaching Hospital
Study ID
NCT06032858
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 59 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Psoriasis is a long standing inflammatory, autoinflammatory disease linked with many comorbidities. Patients with moderate to severe plaque psoriasis can be managed with topical as well as systemic medications. FDA approved Apremilast as first drug to be taken orally in cases of psoriasis in mid 1990's. Currently, according to researchers best knowledge no study has been done on use of Apremilast in Pakistan. It has recently become available here. Keeping in view all the benefits of this drug, a study has been planned to check its effectiveness and safety 30mg twice a day, in patients with moderate to severe chronic plaque psoriasis based on Psoriasis area and severity index and Body surface area assessments in our population.

Key Dates

First listed
Sep 13, 2023
Start date
Mar 6, 2022
Status verified
Sep 2023
Primary completion
Jul 10, 2023
Completion
Aug 10, 2023

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apremilast 30 mg twice daily

Primary Outcome Measure

Psoriasis area and severity index [ Time Frame: 16 weeks ]

Related Studies